TY - JOUR T1 - Early estimates of SARS-CoV-2 B.1.1.7 variant emergence in a university setting JF - medRxiv DO - 10.1101/2021.03.05.21252541 SP - 2021.03.05.21252541 AU - Kaitlyn E. Johnson AU - Spencer Woody AU - Michael Lachmann AU - Spencer J. Fox AU - Jessica Klima AU - Terrance S. Hines AU - Lauren Ancel Meyers Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/03/09/2021.03.05.21252541.abstract N2 - Recent identification of the highly transmissible novel SARS-CoV-2 variant in the United Kingdom (B.1.1.7) has raised concerns for renewed pandemic surges worldwide 1,2. B.1.1.7 was first identified in the US on December 29, 2020 and may become dominant by March 2021 3. However, the regional prevalence of B.1.1.7 is largely unknown because of limited molecular surveillance for SARS-CoV-2 4. Quantitative PCR data from a surveillance testing program on a large university campus with roughly 30,000 students provides local situational awareness at a pivotal moment in the COVID-19 pandemic.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis research was supported by NIH Grant R01 AI151176 and CDC Grant U01 IP00136.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board at the University of Texas at Austin approved the use of quantitative PCR data from the proactive community testing program on 1/15/2021. IRB ID: STUDY00000009-MOD01.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesTest positivity data used in this manuscript is available publicly at the UT Austin COVID-19 Dashboard. Use of deidentified quantitative PCR data was approved by the IRB at UT Austin. https://coronavirus.utexas.edu/ut-austin-covid-19-dashboard ER -